研究目的
To evaluate a novel silica nanoparticle-based agent for its potential use as contrast enhancer in the intraoperative de?nition of tumor free resection margins in head and neck cancer.
研究成果
The EGFR-FITC-SiO2-NPs showed good biocompatibility, successful binding of the EGFR-antibody, and were detected in vitro, in vivo and ex vivo after short incubation times. This nano-contrast agent can improve the real-time in vivo analysis of suspicious mucosa and enables operative tumor border examination by confocal laser endomicroscopy.
研究不足
The amount of EGFR-Ab that was conjugated to the FITC-SiO2-NPs was relatively small and could not be quanti?ed exactly. The synthesis could be modi?ed to enhance EGFR-Ab coupling.
1：Experimental Design and Method Selection:
Synthesis of silica nanoparticles with an average size of 45 nm, modification with fluorescein isocyanate (FITC) and EGFR-targeting antibodies. Evaluation of nanoparticle binding in vitro and in vivo by confocal laser scanning microscopy.
2：Sample Selection and Data Sources:
Human hepatocarcinoma cell line HuH7 and a human base of tongue squamous cell carcinoma cell line HNSCCUM-02T, primary human fibroblasts, and human tissue specimens.
3：List of Experimental Equipment and Materials:
Transmission electron microscope (TEM), Malvern Zetasizer Nano ZS, Fluoroskan Ascent Microplate Reader, Leica DMi8 confocal laser scanning microscope, and others.
4：Experimental Procedures and Operational Workflow:
Nanoparticle synthesis, functionalization, and EGFR-antibody coupling. In vitro and in vivo binding assays, confocal laser scanning microscopy, and confocal endomicroscopy.
5：Data Analysis Methods:
ζ-potential measurements, fluorescence measurements, and statistical analysis.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
